Biotechnology company Lonza has launched a new portfolio for dry-powder inhalation (DPI) capsules, the company has announced.
Capsules
Lonza’s Capsugel Zephyr portfolio has been launched to meet the growing need for customised solutions for optimal pulmonary drug delivery.
Capsugel Zephyr capsules contain highly customisable DPI capsules of different polymers and compositions, as well as product customisation services to help address the specific needs of inhalation drug products manufacturers.
“Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance and is cost-effective to manufacture with various dose carrying capacity. With more than 20 years of experience in manufacturing DPI- capsules, Lonza offers a uniquely customised portfolio of polymers to meet the growing need of inhalation DPI products for pulmonary drug delivery,” said Stef Vanquickenborne, VP R&D, Lonza Pharma & Biotech.
“With the launch of the Capsugel Zephyr capsule portfolio, Lonza will offer full end-to-end solutions for capsule-based DPI products. Our specialised capsule technology provides our customers with the right solution to deliver optimal product performance for the pulmonary route; a testament to how patient-centricity and customer focus are at the heart of Lonza’s healthcare continuum,” said Fabio Invernizzi, VP global sales, Capsule Delivery Solutions, Lonza Pharma & Biotech.